Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells

Anti-Cancer Drugs

Volumn 19, Issue 1, 2008, Pages 55-64

  Chen, Yu Jen ^a   Kuo, Cheng Deng ^b   Tsai, Yin Meng ^c   Yu, Chih Chia ^c   Wang, Guang Sheng ^d   Liao, Hui Fen ^b,c  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^d Wan Hui Pharmaceutical Group   (China)

Author keywords

Adhesion; Anoikis; Colorectal adenocarcinoma; Mitogen activated protein kinase; Norcantharidin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BETA1 INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NORCANTHARIDIN; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR;

ANOIKIS; APOPTOSIS; ARTICLE; BONE MARROW; CANCER CELL; CANCER INHIBITION; CELL ADHESION; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANOIKIS; ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOTTING, WESTERN; BONE MARROW CELLS; BROMODEOXYURIDINE; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DATA INTERPRETATION, STATISTICAL; ENZYME ACTIVATION; FLOW CYTOMETRY; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MONOCYTES;

EID: 36549025029     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f18826     Document Type: Article

References (33)

1. Baba Y, Hirukawa N, Sodeoka M. Optically active cantharidin analogues possessing selective inhibitory activity on Ser/Thr protein phosphatase 2B (calcineurin): implications for the binding mode. Bioorg Med Chem 2005; 13:5164-5170.
2. Wang GS. Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 1989; 26:147-162.
3. Zhang L, Sun X, Zhang ZR. An investigation on liver: targeting microemulsions of norcantharidin. Drug Deliv 2005; 12:289-295.
4. Massicot F, Dutertre-Catella H, Pham-Huy C, Liu XH, Duc HT, Warnet JM. In vitro assessment of renal toxicity and inflammatory events of two protein phosphatase inhibitors cantharidin and nor-cantharidin. Basic Clin Pharmacol Toxicol 2005; 96:26-32.
5. Kok SH, Hong CY, Kuo MY, Lee CH, Lee JJ, Lou IU, et al. Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes. Oral Oncol 2003; 39:19-26.
6. Wu LT, Chung JG, Chen JC, Tsauer W. Effect of norcantharidin on N-acetyltransferase activity in HepG2 cells. Am J Chin Med 2001; 29:161-172.
7. Li JL, Cai YC, Liu XH, Xian LJ. Norcantharidin inhibits DNA replication and induces apoptosis with the cleavage of initiation protein Cdc6 in HL-60 cells. Anticancer Drugs 2006; 17:307-314.
8. Fan YZ, Fu JY, Zhao ZM, Chen CQ. Effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells. W J Gastroenterol 2005; 11:2431-2437.
9. Yang EB, Tang WY, Zhang K, Cheng LY, Mack PO. Norcantharidin inhibits growth of human HepG2 cell-transplanted tumor in nude mice and prolongs host survival. Cancer Lett 1997; 117:93-98.
10. Chen YN, Chen JC, Yin SC, Wang GS, Tsauer W, Hsu SF, et al. Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer 2002; 100:158-165.
11. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13:555-562.
12. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004; 430:1034-1039.
13. Bharadwaj S, Thanawala R, Bon G, Falcioni R, Prasad GL. Resensitization of breast cancer cells to anoikis by Tropomyosin-1: role of Rho kinase-dependent cytoskeleton and adhesion. Oncogene 2005; 24:8291-8303.
14. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, et al. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 1999; 18:7034-7045.
15. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001; 264:42-55.
16. Chen YJ, Shieh CJ, Tsai TH, Kuo CD, Ho LT, Liu TY, et al. Inhibitory effect of norcantharidin, a derivative compound from blister beetles, on tumor invasion and metastasis in CT26 colorectal adenocarcinoma cells. Anticancer Drugs 2005; 16:293-299.
17. Rami'rez CJ, Haberbusch JM, Soprano DR, Soprano KJ. Retinoic acid induced repression of AP-1 activity is mediated by protein phosphatase 2A in ovarian carcinoma cells. J Cell Biochem 2005; 96:170-182.
18. Davis RJ. MAPKs: new JNK expands the group. Trends Biochem Sci 1994; 19:470-473.
19. Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 1999; 11:211-218.
20. Nelson JM, Fry DW. Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 2001; 276:14842-14847.
21. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4:937-947.
22. Kikuchi M, Harris DL, Obara Y, Senoo T, Joyce NC. p27kip1 antisense-induced proliferative activity of rat corneal endothelial cells. Invest Ophthalmol Vis Sci 2004; 45:1763-1770.
23. Frisch SM, Francis H. Disruption of epithelial cell - matrix interactions induces apoptosis. J Cell Biol 1994; 124:619-626.
24. Meredith JE Jr, Schwartz M. Integrins, adhesion and apoptosis. Trends Cell Biol 1997; 7:146-150.
25. Frisch SM, Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol 1997; 9:701-706.
26. Chen CS, Mrkisch M, Huang S, Whitesides GM, Ingber D. Geometric control of cell life and death. Science 1997; 276:1425-1428.
27. Kok SH, Cheng SJ, Hong CY, Lee JJ, Lin SK, Kuo YS, et al. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Cancer Lett 2005; 217:43-52.
28. 2-terminal kinase signaling pathways in human hepatoma HepG2 cells. Br J Pharmacol 2003; 140:461-470.
29. Karin M, Gallagher E. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 2005; 57:283-295.
30. Givant-Horwitz V, Davidson B, Lazarovici P, Schaefer E, Nesland JM, Trope CG, et al. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol 2003; 91:160-172.
31. Wu GS. The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther 2004; 3:156-161.
32. 2-terminal kinases in resveratrol-induced activation of p53 and apoptosis. Mol Carcinog 2002; 33:244-250.
33. Li AE, Ito H, Rovira II, Kim KS, Takeda K, Yu ZY, et al. A role for reactive oxygen species in endothelial cell anoikis. Circ Res 1999; 85:304-310.